Safety Study of INCB123667 in Adults With Liver Damage
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Immune system & allergy clinical trials.
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have moderate or severe liver impairment (measured by Child-Pugh score)
- You weigh within a healthy range (BMI 18.0–43.0 kg/m²)
- You do not smoke more than 10 cigarettes per day in the month before screening
- You are willing to use birth control or avoid pregnancy/fathering children during the study
- Your liver condition has been stable for at least 30 days before screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
This study tests a new medicine (INCA033989) given as a shot or IV in healthy adults to see how the body processes it and if it's safe.
This study tests how a new experimental drug (INCB123667) works and is tolerated in adults with severe kidney problems or end-stage kidney disease. Researchers want to understand how the drug moves through the body and whether it's safe for people in your situation.
This study tests an experimental drug called INCB161734 in people with severe kidney disease or those on dialysis. It aims to see how the drug behaves in the body and if it is safe.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This trial tests how a new medicine, BI 1291583, enters the blood in people who have different levels of liver function (from normal to mild, moderate, or severe liver problems). It helps doctors understand if the dose needs to be adjusted for liver health.
Hear when a new Hepatic Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.